Showing results (141-150 of 183) with videos related to

Sort By:
Pageof 19
The Annals of Thoracic Surgery|March 4, 2022
Fluid Accumulation After Neonatal Congenital Cardiac Operation: Clinical Implications and OutcomesDavid K Bailly, Jeffrey A Alten, Katja M Gist, et al.
Gastroenterology|October 5, 2019
Mutated CEACAMs Disrupt Transforming Growth Factor Beta Signaling and Alter the Intestinal Microbiome to Promote Colorectal CarcinogenesisShoujun Gu, Sobia Zaidi, Md Imtaiyaz Hassan, et al.
Plos One|September 7, 2012
Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibilityIndra Adrianto, Chee Paul Lin, Jessica J Hale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavityRobert J Morgan, Timothy W Synold, Bixin Xi, et al.
Cancer Research|March 5, 2020
Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFβ SignalingJian Chen, Abhisek Mitra, Shulin Li, et al.
Transplantation and Cellular Therapy|October 24, 2024
Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17pCurtis Marcoux, Oren Pasvolsky, Denái R Milton, et al.
Transplantation and Cellular Therapy|September 6, 2023
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple MyelomaOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Cancer|December 21, 2023
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantationOren Pasvolsky, Sarah Pasyar, Roland L Bassett, et al.
The Lancet. Haematology|July 18, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trialVania Hungria, Marek Hus, ChengCheng Fu, et al.
British Journal of Haematology|March 6, 2024
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantationKamal Alzahrani, Oren Pasvolsky, Zhongya Wang, et al.
Pageof 19